


Status: Currently Official on 13-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-BF90764D-BC8D-4A35-826F-0EF2F8198CD2_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M3080_02_01
 DOI Ref: k1pcg

© 2025 USPC
 Do not distribute

Aminophylline



$C_{16}H_{24}N_4O_4$ 420.43

$C_{16}H_{24}N_4O_4 \cdot 2H_2O$ 456.46

1*H*-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1);

Theophylline compound with ethylenediamine (2:1).

Anhydrous CAS RN®: 317-34-0; UNII: 27Y3KJK423.

Dihydrate CAS RN®: 5897-66-5; UNII: C229N9DX94.

DEFINITION

Aminophylline is anhydrous or contains NMT two molecules of water of hydration. It contains NLT 84.0% and NMT 87.4% of anhydrous theophylline ($C_7H_8N_4O_2$), calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: 197A or 197K. ▲ (CN 1-May-2020)

Sample: 500 mg of Aminophylline

Analysis: Dissolve the *Sample* in 20 mL of [water](#), add, with constant stirring, 1 mL of [3 N hydrochloric acid](#), filter (retain the filtrate), wash the precipitate with small portions of cold [water](#), and dry at 105° for 1 h.

Acceptance criteria: The IR spectrum of theophylline so obtained corresponds to that of [USP Theophylline RS](#).

- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

- **C.**

Sample: The filtrate obtained in *Identification A*.

Analysis: To the *Sample* add 0.5 mL of [benzenesulfonyl chloride](#) and 5 mL of [1 N sodium hydroxide](#) to render alkaline. Shake by mechanical means for 10 min, add 5 mL of [3 N hydrochloric acid](#) to acidify, chill, collect the precipitated disulfonamide of ethylenediamine, wash with [water](#), recrystallize from [water](#), and dry at 105° for 1 h.

Acceptance criteria: The dried precipitate melts at 164°–171°.

ASSAY

PROCEDURE

Solution A: 10 mM [ammonium acetate](#) prepared as follows. Transfer 770.8 mg of [ammonium acetate](#) to a 1-L volumetric flask, and dissolve in [water](#) to 80% of the flask volume. Adjust with [glacial acetic acid](#) to a pH of 5.5, and dilute with [water](#) to volume. Pass through a suitable filter of 0.2-µm pore size.

Solution B: Methanol

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	98	2
7	50	50
7.3	10	90

Time (min)	Solution A (%)	Solution B (%)
8.3	10	90
8.31	98	2
12	98	2

Impurity stock solution: 25 µg/mL of [USP Theophylline Related Compound F RS](#) in [water](#)

System suitability solution: 0.8 mg/mL of [USP Theophylline RS](#) and 1 µg/mL of [USP Theophylline Related Compound F RS](#) in [water](#) prepared as follows. Transfer 21 mg of [USP Theophylline RS](#) to a 25-mL volumetric flask and add 15 mL of [water](#). Sonicate to dissolve, add 1 mL of *Impurity stock solution*, and dilute with [water](#) to volume.

Standard solution: 0.17 mg/mL of [USP Theophylline RS](#) in [water](#). Sonicate to dissolve as needed.

Sample solution: 0.2 mg/mL of Aminophylline in [water](#)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 270 nm

Column: 2.1-mm × 10-cm; 1.7-µm packing [L1](#)

Column temperature: 40°

Flow rate: 0.4 mL/min

Injection volume: 1 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 2.0 between theophylline and theophylline related compound F, *System suitability solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of theophylline (C₇H₈N₄O₂) in the portion of Aminophylline taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of theophylline from the *Sample solution*

r_S = peak response of theophylline from the *Standard solution*

C_S = concentration of [USP Theophylline RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Aminophylline in the *Sample solution* (mg/mL)

Acceptance criteria: 84.0%–87.4% of theophylline on the anhydrous basis

OTHER COMPONENTS

• CONTENT OF ETHYLENEDIAMINE

Sample: 500 mg of Aminophylline

Diluent: [Water](#)

Titrimetric system

Mode: Direct titration

Titrant: [0.1 N hydrochloric acid VS](#)

Endpoint detection: Visual

Analysis: Dissolve the *Sample* in 30 mL of *Diluent*, add [methyl orange TS](#), and titrate. Each mL of 0.1 N hydrochloric acid is equivalent to 3.005 mg of ethylenediamine (C₂H₈N₂).

Acceptance criteria: 157–175 mg of ethylenediamine (C₂H₈N₂) per gram of theophylline (C₇H₈N₄O₂) found in the Assay

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.15%

• ORGANIC IMPURITIES

Solution A, Solution B, Mobile phase, System suitability solution, and Chromatographic system: Proceed as directed in the Assay.

Standard stock solution: 25.0 µg/mL each of [USP Caffeine RS](#), [USP Theophylline RS](#), [USP Theophylline Related Compound B RS](#), [USP Theophylline Related Compound C RS](#), [USP Theophylline Related Compound D RS](#), and [USP Theophylline Related Compound F RS](#) in [water](#)

Standard solution: 1.0 µg/mL each of [USP Caffeine RS](#), [USP Theophylline RS](#), [USP Theophylline Related Compound B RS](#), [USP Theophylline Related Compound C RS](#), [USP Theophylline Related Compound D RS](#), and [USP Theophylline Related Compound F RS](#) in [water](#), from *Standard stock solution*

Sample solution: 1.0 mg/mL of Aminophylline in [water](#)

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 2.0 between theophylline and theophylline related compound F, *System suitability solution*

Relative standard deviation: NMT 3.0% for each peak, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of caffeine, theophylline related compound B, theophylline related compound C, theophylline related compound D, and theophylline related compound F in the portion of Aminophylline taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of caffeine, theophylline related compound B, theophylline related compound C, theophylline related compound D, or theophylline related compound F from the *Sample solution*

r_S = peak response of the corresponding Reference Standard from the *Standard solution*

C_S = concentration of the corresponding Reference Standard in the *Standard solution* (mg/mL)

C_U = concentration of Aminophylline in the *Sample solution* (mg/mL)

Calculate the percentage of dimethyl uric acid, theobromine, and any other individual unspecified impurity in the portion of Aminophylline taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of dimethyl uric acid, theobromine, or any other individual unspecified impurity from the *Sample solution*

r_S = peak response of theophylline from the *Standard solution*

C_S = concentration of [USP Theophylline RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Aminophylline in the *Sample solution* (mg/mL)

F = relative response factor

Acceptance criteria: See [Table 2](#). Disregard peaks less than 0.05%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Theophylline related compound C	0.36	—	0.10
Theophylline related compound B	0.63	—	0.10
Theophylline related compound D	0.69	—	0.10
Dimethyl uric acid ^a	0.76	0.55	0.10
Theobromine ^b	0.82	1.0	0.10
Theophylline	1.0	—	—
Theophylline related compound F	1.09	—	0.10

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Caffeine	1.20	—	0.10
Any other individual unspecified impurity	—	1.0	0.10
Total impurities	—	—	0.3

^a 1,3-Dimethyl-7,9-dihydro-1*H*-purine-2,6,8(3*H*)-trione.

^b 3,7-Dihydro-3,7-dimethylpurine-2,6(1*H*)-dione.

SPECIFIC TESTS

- [WATER DETERMINATION \(921\), Method I](#)

Sample: 1.5 g of Aminophylline

Solvent: 50 mL of [chloroform](#) and [anhydrous methanol](#) (50:50) in place of [anhydrous methanol](#)

Acceptance criteria

Anhydrous: NMT 0.75%

Hydrous: NMT 7.9%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.
- **LABELING:** Label it to indicate whether it is anhydrous or hydrous, and also to state the content of anhydrous theophylline.
- **USP REFERENCE STANDARDS (11).**

[USP Caffeine RS](#)

[USP Theophylline RS](#)

[USP Theophylline Related Compound B RS](#)

3-Methyl-1*H*-purine-2,6-dione;

Also known as 3-Methyl-3,7-dihydro-1*H*-purine-2,6-dione.

$C_6H_6N_4O_2$ 166.14

[USP Theophylline Related Compound C RS](#)

N-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)formamide.

$C_7H_{10}N_4O_3$ 198.18

[USP Theophylline Related Compound D RS](#)

Theophyllidine;

N-Methyl-5-(methylamino)-1*H*-imidazole-4-carboxamide hydrochloride monohydrate.

$C_6H_{10}N_4O \cdot HCl \cdot H_2O$ 208.65

[USP Theophylline Related Compound F RS](#)

7-(2-Hydroxyethyl)-1,3-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione.

$C_9H_{12}N_4O_3$ 224.22

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
AMINOPHYLLINE	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(1)

Current DocID: GUID-BF90764D-BC8D-4A35-826F-0EF2F8198CD2_2_en-US

DOI: https://doi.org/10.31003/USPNF_M3080_02_01

DOI ref: [k1pcg](#)